US1588252A - Preparation of solutions of derivatives of dioxydiaminoarsenobenzene - Google Patents

Preparation of solutions of derivatives of dioxydiaminoarsenobenzene Download PDF

Info

Publication number
US1588252A
US1588252A US679251A US67925123A US1588252A US 1588252 A US1588252 A US 1588252A US 679251 A US679251 A US 679251A US 67925123 A US67925123 A US 67925123A US 1588252 A US1588252 A US 1588252A
Authority
US
United States
Prior art keywords
solution
solutions
sulphite
sugar
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US679251A
Inventor
Stuart R Macewen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US679251A priority Critical patent/US1588252A/en
Application granted granted Critical
Publication of US1588252A publication Critical patent/US1588252A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • This invention relates to the preparation of solutions of the arsenical drugs commonly known as arsphenamine, neoarsphenamine, sulpharsphenamine and the like, and which are derivatives of dioxydiaminoarsenobenzene, and particularly to solutions of sodium dioxydiaminoarsenobenzene-methanalsulphoxylate, disodiumdioxydiaminoarsenobenzene and the sulpharsphenamine above referred to and which is described in the Public Health Reports of the United States Government pp. 27832798 vol. 37, No. 45.
  • These substances are at present usually sold in powder form and the solutions for injection are made at the time of use, since solutions as now made rapidly become toxic.
  • My invention therefore lies in the discovery that by the use of both the reducing agent and the sugar a solution may be produced which will keep for periods many times longer than a solution prepared with either alone, and that the keeping effeet is many times greater than the sum of the individual effects of the two reagents.
  • a reducing agent such as an acid sulphite or hydrosulphite or sulphurous acid free or combined with abase, or the unsaturated thio acids, free or combined with a base.
  • Another unexpected result of this invention is that the toxicity of the freshly made solution is materially reduced, being very much less than the toxicity of a solution prepared from the powder form of the drug in the ordinary manner, and this reduced toxicity is maintained as long as the solution has therapeutic value.
  • sulphites which I have found to work more or less satisfactorily are potassium acid sulphite and ammonium acid sulphite and pottassium and sodium meta bi sulphites.
  • the alkali is used to-overcome the tendeney oi solutions of sulph-arsphenamine to gel, sufficient being used to bring the solution to a condition in which it is only slightly acid.
  • hydrosulphite is preferably added last as in this case the acidity of the sod; hydro-sulphite need not be: taken into account in calculating the quantity of alkali required.
  • What I claim is 1. A stable non-jellying solution of 'sulph arsphenainine containing a sugar, a soluble inorganic preservative, and an alkaline reagent.
  • a r 2.' A stable non-jellying solutionof sulpharsphenainine containing a sugar, a soluble 1 preservative, and an alkaline re-agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Description

Patented June 8, 1926.
' UNITED STATES PATENT/OFFICE;
sTuAR'r n. MAcnwEN, or TORONTQONTARIO, earmna PREPARATION OF SOLUTIONS or DERIVATIVES or nIoxYnIAMmoansnivoiannznnn No Drawing. Original application filed'lvllay 31, 1928, Serial No. 642,704. Divided and this application filed December 7, 1923. Serial 110,679,251.
This application is a division of my prior application No. 64.2,704, filed May 31st, 1923.
This invention relates to the preparation of solutions of the arsenical drugs commonly known as arsphenamine, neoarsphenamine, sulpharsphenamine and the like, and which are derivatives of dioxydiaminoarsenobenzene, and particularly to solutions of sodium dioxydiaminoarsenobenzene-methanalsulphoxylate, disodiumdioxydiaminoarsenobenzene and the sulpharsphenamine above referred to and which is described in the Public Health Reports of the United States Government pp. 27832798 vol. 37, No. 45. These substances are at present usually sold in powder form and the solutions for injection are made at the time of use, since solutions as now made rapidly become toxic. As solutions must be made with great care, it is desirable that they be made only by thoroughly competent persons, and it is also desirable to save the administrator the time and trouble involved in the making of the solutions. My object therefore is to devise a method of making solutions ready for use which will keep for long periods of time without developing toxicity. I am aware that it has been proposed to employ an inorganic reducing agent such as sodium hy-dro-sulphite to give increased stability to solutions of arsenical drugs, and also that sugar has been employed for that purpose, but it has not so far been proposed to employ both in the same solution. My invention therefore lies in the discovery that by the use of both the reducing agent and the sugar a solution may be produced which will keep for periods many times longer than a solution prepared with either alone, and that the keeping effeet is many times greater than the sum of the individual effects of the two reagents.
I attain my object by adding to the solution of the drug in water, one or more of the group termed in chemistry sugars, and a reducing agent such as an acid sulphite or hydrosulphite or sulphurous acid free or combined with abase, or the unsaturated thio acids, free or combined with a base.
Experiments so far show that substantially pure dextrose and sodium acid-sulphite (NaI-ISO give very satisfactory results, The amount of both the sugar and sodium acid-sulphite may vary considerably.
In practice I havefound that',-assuming solution containing 5 grammes of sodiumdioxydiaminoarsenobenzene methanal-sulphoxylate to be required, it may be prepared by dissolving it with 20 grammes of dextrose and 5 grammes of sodium acid-sulphite in 100 c. c. of water. I have also used larger proportions ofboth the sugar and of the sulphite, If'a stronger solution of the drug be required, a larger quantity both of the sugar and sulphite may be used. Care must be taken, however, not to use so much sugar that the solution becomes too viscous, or so much of the'sulphite as to have an irritating effect on the patient.
WVhile either the sugar or the sulphite alone have a marked effect in preventing the solution becoming toxic by keeping, I find that when used together there is an increased effeet several times greater than their indi vidual effects.
Another unexpected result of this invention is that the toxicity of the freshly made solution is materially reduced, being very much less than the toxicity of a solution prepared from the powder form of the drug in the ordinary manner, and this reduced toxicity is maintained as long as the solution has therapeutic value.
Other sulphites which I have found to work more or less satisfactorily are potassium acid sulphite and ammonium acid sulphite and pottassium and sodium meta bi sulphites.
The solution after preparation is put up in sealed ampules for distribution, and will be found to keep satisfactorily for long periods.
In preparing sulph-arsphenamine I have obtained a solution well adapted for sub cutaneous injection by using the following proportions.
5 grammes sulph-arsphenamine.
gramme sod. hydro-sulphite.
12 grammes dextrose.
20 c, 0. water.
3 c. c. 1 normal caustic soda solution.
The alkali is used to-overcome the tendeney oi solutions of sulph-arsphenamine to gel, sufficient being used to bring the solution to a condition in which it is only slightly acid.
In preparing the solution the sod. hydrosulphite is preferably added last as in this case the acidity of the sod; hydro-sulphite need not be: taken into account in calculating the quantity of alkali required.
What I claim is 1. A stable non-jellying solution of 'sulph arsphenainine containing a sugar, a soluble inorganic preservative, and an alkaline reagent. A r 2.' A stable non-jellying solutionof sulpharsphenainine containing a sugar, a soluble 1 preservative, and an alkaline re-agent.
3. A stable non-jellying' solution of sulpln arsphenamine containing a sugar, a soluble reducing agent, and an alkaline re-agent' 4. A stable non-jellying solution of sulpharsphenarnine containing a sugar, a soluble inorganic reducing agent, and an alkaline re-agent. g
V Signed at Bufialo,N. Y., this 30th clay of November 1923;
STUART R. MAoElVEN.
US679251A 1923-05-31 1923-12-07 Preparation of solutions of derivatives of dioxydiaminoarsenobenzene Expired - Lifetime US1588252A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US679251A US1588252A (en) 1923-05-31 1923-12-07 Preparation of solutions of derivatives of dioxydiaminoarsenobenzene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64270423A 1923-05-31 1923-05-31
US679251A US1588252A (en) 1923-05-31 1923-12-07 Preparation of solutions of derivatives of dioxydiaminoarsenobenzene

Publications (1)

Publication Number Publication Date
US1588252A true US1588252A (en) 1926-06-08

Family

ID=27094091

Family Applications (1)

Application Number Title Priority Date Filing Date
US679251A Expired - Lifetime US1588252A (en) 1923-05-31 1923-12-07 Preparation of solutions of derivatives of dioxydiaminoarsenobenzene

Country Status (1)

Country Link
US (1) US1588252A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10423910B2 (en) 2017-03-29 2019-09-24 Walmart Apollo, Llc Retail inventory supply chain management
US10643170B2 (en) 2017-01-30 2020-05-05 Walmart Apollo, Llc Systems, methods and apparatus for distribution of products and supply chain management

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10643170B2 (en) 2017-01-30 2020-05-05 Walmart Apollo, Llc Systems, methods and apparatus for distribution of products and supply chain management
US10423910B2 (en) 2017-03-29 2019-09-24 Walmart Apollo, Llc Retail inventory supply chain management

Similar Documents

Publication Publication Date Title
ATE5125T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING SANGUINARIA AND GALANGAL FOR THE TREATMENT OF PERIODONTITIS AND TUMORS.
US2701781A (en) Aqueous chlorine dioxide antiseptic compositions and production thereof
US1588252A (en) Preparation of solutions of derivatives of dioxydiaminoarsenobenzene
US1921722A (en) Solvent for remedies
US3898330A (en) Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US1615989A (en) Preparation of solutions of derivatives of dioxydiaminoarsenobenzene
US2719812A (en) Stabilized aqueous solutions of streptomycin
AT407113B (en) COMPOSITION IN THE FORM OF AN AQUEOUS THICKENED PREPARATION FOR PERORAL ADMINISTRATION WITH N-ACETYLCYSTONE
US3138528A (en) Stable, aqueous solutions of 21-phosphate esters of 21-hydroxy steroids
US1764996A (en) Stable effervescent composition
US2888381A (en) Solutions of citrus bioflavonoids
GB667114A (en) Improvements in or relating to the manufacture of jelly powder
US2145869A (en) Intravenous therapy for the treatment of syphilis
Regan et al. The physiologic action of dehydrocholic acid
US2152236A (en) Insecticide
EP0119156B1 (en) Prostaglandin-containing pharmaceutical composition and its preparation
DE1617433C (en) Process for the preparation of 5.5 Diphenyl hydantoin sodium solutions for injections
US1451850A (en) Mercurial composition
US1383493A (en) Ointment
AT92889B (en) Process for the production of long-lasting, rapidly soluble silver protein preparations.
GB1224676A (en) Novel benzylthioethylamines, processes for their preparation, and compositions incorporating them
US1569956A (en) Method of producing a pharmaceutical preparation and a pharmaceutical preparation thus produced
AT311332B (en) Process for the preparation of a new ester of 3,3-bis (p-hydroxyphenyl) -2-indolinone and its salts
DE862341C (en) Process for the preparation of aqueous solutions of derivatives of p-aminobenzene sulfonamide
US1697910A (en) Solution of ammonium salt of hydroxyacetylaminophenylarsenic acid